



NDA 215152/S-015
NDA 215153/S-014

SUPPLEMENT APPROVAL

Phathom Pharmaceuticals, Inc.
Attention: Nancianne Knipfer, PhD, RAC
Vice President, Regulatory Affairs and Medical Writing
2150 East Lake Cook Road, Suite 800
Buffalo Grove, IL 60089

Dear Dr. Knipfer:

Please refer to your supplemental new drug applications (sNDAs) dated and received May 21, 2025, submitted pursuant to section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act (FDCA) for the following:

NDA 215152: Voquezna Triple Pak (vonoprazan tablets; amoxicillin capsules; clarithromycin tablets) 20 mg, 500 mg, 500 mg, co-packaged

NDA 215153: Voquezna Dual Pak (vonoprazan tablets; amoxicillin capsules) 20 mg, 500 mg, co-packaged.

These “Changes Being Effected” sNDAs provide for revisions to the prescribing information (PI), **ADVERSE REACTIONS (6)** section, **Postmarketing Experience with Components of VOQUEZNA TRIPLE PAK and VOQUEZNA DUAL PAK (6.2)** subsection, that were approved under the supplements on May 1, 2024, but omitted from the PI approved under the supplements on July 31, 2024. Additionally, minor editorial changes were made through out the PI.

APPROVAL & LABELING

We have completed our review of these applications. They are approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at FDA.gov.¹ Content of labeling must be identical to the enclosed labeling (text for the

¹ <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>

Prescribing Information), with the addition of any labeling changes in pending “Changes Being Effected” (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling. If the content of labeling in SPL format initially submitted with this CBE-0 labeling supplement is identical to the attached approved labeling, an additional submission of content of labeling in SPL format is not required.

Information on submitting SPL files using eList may be found in the guidance for industry *SPL Standard for Content of Labeling Technical Qs and As*.²

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in Microsoft Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes. To facilitate review of your submission(s), provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

PATENT LISTING REQUIREMENTS

Pursuant to 21 CFR 314.53(d)(2) and 314.70(f), certain changes to an approved NDA submitted in a supplement require you to submit patent information for listing in the Orange Book upon approval of the supplement. You must submit the patent information required by 21 CFR 314.53(d)(2)(i)(A) through (C) and 314.53(d)(2)(ii)(A) and (C), as applicable, to FDA on Form FDA 3542 within 30 days after the date of approval of the supplement for the patent information to be timely filed (see 21 CFR 314.53(c)(2)(ii)). You also must ensure that any changes to your approved NDA that require the submission of a request to remove patent information from the Orange Book are submitted to FDA at the time of approval of the supplement pursuant to 21 CFR 314.53(d)(2)(ii)(B) and 314.53(f)(2)(iv).

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

² We update guidances periodically. For the most recent version of a guidance, check the FDA Guidance Documents Database <https://www.fda.gov/RegulatoryInformation/Guidances/default.htm>.

NDA 215152/S-015
NDA 215153/S-014

Page 3

If you have any questions, contact Eva Zuffova, PhD, MS, Senior Regulatory Health Project Manager, at 301-796-0697 or eva.zuffova@fda.hhs.gov.

Sincerely,

{See appended electronic signature page}

Mukil Natarajan, MD
Deputy Director for Safety
Division of Anti-Infectives
Office of Infectious Diseases
Office of New Drugs
Center for Drug Evaluation and Research

ENCLOSURE:

- Content of Labeling

This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

/s/

MUKILAN NATARAJAN
06/12/2025 03:24:13 PM